Trial Profile
COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Vicriviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions
- Acronyms COVER
- Sponsors Merck & Co; Schering-Plough
- 02 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2008 Planned end date changed from 1 Sep 2012 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 15 Jul 2008 New trial record.